The international surgical journal with global reach

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-1626.

Published: 22nd July 2020

Authors: Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ et al.

Conclusion

A total of 4096 patients were randomly allocated one of three schedules of radiotherapy over one to three weeks. After a median follow-up of 71.5 months, the risk of ipsilateral breast cancer recurrence was non-inferior, and breast tissue effects were least, for the one week schedule of 26 Gy fractions.

Pubmed Link